Literature DB >> 15166918

Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).

Jan Jacques Michiels1, Zwi N Berneman, Marc van der Planken, Wilfried Schroyens, Ulrich Budde, Huub H D M van Vliet.   

Abstract

The parameters to diagnose von Willebrand disease (vWD) include factor VIII coagulant activity (FVIII:C), von Willebrand factor antigen (vWF:Ag), von Willebrand factor ristocetin cofactor activity (vWF:RCo), and von Willebrand factor collagen binding activity (vWF:CB). Type 2 vWD is associated with a moderate bleeding diathesis due to low levels of vWF:RCo and vWF:CB as compared with near normal or normal values for FVIII:C and vWF:Ag. As the factor VIII/von Willebrand factor (vWF) concentrate, Haemate-P, is featured by a vWF:RCo/FVIII:C ratio of about 2.2, the recommended loading dose of 50 U/kg FVIII:C followed by 25 U/kg FVIII:C every 12 h for several days for bleeding prophylaxis in type 2 vWD patients undergoing major surgery demonstrated a predicted significant over-treatment reaching vWF:RCo levels above 2 U/ml. Therefore, we restricted Haemate-P substitution for major surgery to one loading dose of 40-50 U/kg FVIII:C (88-110 U/kg vWF:RCo) followed by 15-20 U/kg FVIII:C (33-44 U/kg vWF:RCo) every 12 h for several days and evaluated this strategy in a prospective pharmacokinetic and efficacy study for bleeding prophylaxis in five type 2 vWD patients. Pre-treatment and peak levels (1 h after Haemate-P loading dose) rose from 0.43-0.66 to 1.5-2.5 U/ml for FVIII:C, from 0.23-0.45 to 1.5-2.5 U/ml for vWF:Ag, from 0.10-< 0.20 to 1.5-2.5 U/ml for vWF:RCo, and from < 0.05-0.10 to 1.0-2.0 U/ml for vWF:CB. Mean in vivo recoveries per transfused IU FVIII:C/kg body weight were 3.2% for FVIII:C, 3.9% for vWF:RCo, and 2.8% for vWF:CB. Mean in vivo recoveries per transfused IU vWF:RCo/kg were 1.45% for FVIII:C, 1.7% for vWF:RCo and 1.25% for vWF:CB. The biological half-life times after transfused Haemate-P were about 12 h for both vWF:RCo and vWF:CB. Based on these pharmacokinetic data, we propose to adapt the loading dose factor VIII/vWF concentrate (Haemate-P) to 60-80 U/kg vWF:RCo followed by 30-40 U/kg vWF:RCo every 12 h for no longer than several days (less than 1 week) for bleeding prophylaxis during major surgery or trauma, and to one loading dose of 40-60 U/kg vWF:RCo for minor surgery, trauma or mucotaneous bleedings in patients with type 2 vWD unresponsive to DDAVP.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15166918     DOI: 10.1097/00001721-200406000-00006

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  5 in total

1.  Antihemophilic Factor/von Willebrand Factor Complex (Human), Dried, Pasteurized.

Authors: 
Journal:  P T       Date:  2010-01

Review 2.  Surgical prophylaxis in von Willebrand's disease: a difficult balance to manage.

Authors:  Massimo Franchini
Journal:  Blood Transfus       Date:  2008-09       Impact factor: 3.443

3.  Prophylactic efficacy and pharmacokinetically guided dosing of a von Willebrand factor/factor VIII concentrate in adults and children with von Willebrand's disease undergoing elective surgery: a pooled and comparative analysis of data from USA and European Union clinical trials.

Authors:  Pier Mannuccio Mannucci; Paul Alexander Kyrle; Sam Schulman; Jorge Di Paola; Reinhard Schneppenheim; Joan Cox Gill
Journal:  Blood Transfus       Date:  2013-04-17       Impact factor: 3.443

Review 4.  Human plasma von Willebrand factor/factor VIII complex (Haemate P/Humate-P): in von Willebrand disease and haemophilia A.

Authors:  Natalie J Carter; Lesley J Scott
Journal:  Drugs       Date:  2007       Impact factor: 9.546

5.  Perioperative onset of acquired von Willebrand syndrome: Comparison between HVAD, HeartMate II and on-pump coronary bypass surgery.

Authors:  Christina Feldmann; Rashad Zayat; Andreas Goetzenich; Ali Aljalloud; Eva Woelke; Judith Maas; Lachmandath Tewarie; Thomas Schmitz-Rode; Ruediger Autschbach; Ulrich Steinseifer; Ajay Moza
Journal:  PLoS One       Date:  2017-02-24       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.